China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline.
Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study.
The journal is included in CA, JST and CSCD.
Honorary Editor-in-Chief Xiao Peigen Editor-in-Chief Wang Yongyan
Associate Editors Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board Cai Shaoqing, Chen Shilin
To systematically evaluate the efficacy and safety of breviscapine injection in the treatment of unstable angina pectoris (UAP). Eight electronic databases and clinical trials registries were searched to collect randomized controlled trials on breviscapine injection in the treatment of UAP. According to the evaluation standards in Cochrane Handbook 5.1, two independent reviewers screened out the literature, extracted data and assessed the quality of the studies included. RevMan 5. 3 software was used for Meta quantitative analysis and corresponding description analysis. A total of 36 studies involving 3 058 patients were included, 1 552 cases in the trial group, 1 506 cases in the control group, 1 846 males and 1 212 females. All the clinical studies showed a low quality. Meta-analysis results showed that the combination of breviscapine injection and conventional therapy was superior to conventional therapy in angina pectoris efficacy (RR
angina pectoris efficacy = 1.29, 95% CI [1.23, 1.35],
P < 0.000 01; RR
ECG1 = 1.25, 95% CI [1.12, 1.38],
P < 0.000 1; RR
ECG2 = 1.38, 95% CI [1.27, 1.49],
P < 0.000 01); descriptive analysis of a single study showed that the efficacy of combination of breviscapine injection and conventional therapy was superior to that of conventional therapy alone. In respect of hemorheology, the combination of breviscapine injection and conventional therapy was better than conventional therapy in lowering LBV and EAI (MD
LBV = −1.27, 95% CI [−1.55, −0.99],
P < 0.000 01; MD
EAI= −0.38, 95% CI [−0.60, −0.16],
P = 0.000 6), as well as in lowering WBV and HCT in the descriptive analysis of single study. In respect of blood lipid, the combination of breviscapine injection and conventional therapy was better than conventional therapy in lowering TC, TG and LDL-C (MD
TC = −0.30, 95% CI [−0.51, −0.10],
P = 0.003; MD
TG = −0.32, 95% CI [−0.77, 0.13],
P = 0.16; MD
LDL-C = −0.45, 95% CI [−0.76, −0.14],
P = 0.004). In reducing the frequency of angina attacks, heart rate, high sensitive C-reactive protein and improving exercise tolerance, the combination of breviscapine injection and conventional therapy was also superior to the conventional therapy alone (MD
FAP = −3.30, 95% CI [−4.06, −2.54],
P < 0.000 01; MD
HR = −9.38, 95% CI [−12.78, −5.98],
P = 0.000 2; MD
hs-CRP = −0.56, 95% CI [−0.85, −0.27],
P = 0.000 2; MD
ET = 0.88, 95% CI [0.41, 1.35],
P = 0.000 2). The main adverse reactions in the two groups included headache, dizziness, palpitations, nausea, abdominal distension, skin pruritus, flushes and allergic reactions in the study. The safety of breviscapine injection needs to be further studied and clarified because of the combination of drugs and the incomplete information reported in the original study. The current evidence suggested that the combination of breviscapine injection and conventional therapy had certain advantages in curative effect for the treatment of UAP. Due to the low quality of the study and its own shortcomings, it is necessary to design more rigorous, high-quality, multi-center randomized double-blind controlled trials to increase the strength of the evidence.
To identify the metabolites of Danshensu in plasma and urine in rats by using UHPLC–LTQ-Orbitrap method. After oral gavage of Danshensu CMC-Na suspension in SD rats, urine and plasma samples were collected and processed by solid phase extraction. ACQUITY UPLC BEH C
18 column (2.1 mm × 100 mm, 1.7 μm) was utilized, with 0.1% formic acid (A)–acetonitrile (B) solution as the mobile phase for gradient elution. Negative electrospray ion mode based data-acquisition method was established to collect the mass spectrometry data of biological samples. As a result, Danshensu and 21 Danshensu Ⅰ phase and Ⅱ phase metabolites were finally identified according to the accurate mass measurements, mass fragmentation behaviors and comparing with the reference standards. The main metabolic pathways included dehydration, methylation, glucuronide conjugation, sulfate conjugation and their composite reactions. Consequently, our study expounded metabolites of Danshensu in rats based on UHPLC–LTQ-Orbitrap method and provided a reference for further researches on therapeutic material basis and mechanism of Danshensu.
Ligustrazine is an important active ingredient of the traditional Chinese medicine Chuanxiong Rhizoma, but its content is a controversial topic. The endophytes of medicinal plants have the ability to produce the same active substances as the host, so this report focused on the endophytic
Bacillus subtilis, to study the origin of ligustrazine in Chuanxiong Rhizoma preliminarily by inoculating the isolated endophytic
B. subtilis to the Chuanxiong Rhizoma medium in vitro for solid state fermentation. Tissue grinding method was used to isolate the endogenetic
B. subtilis. The morphological features, conventional physiological and biochemical reactions and 16S rRNA molecular techniques were combined to identify the endogenetic strains. Then, the strains that grew well in the medicinal matrix of Chuanxiong Rhizoma were screened out for further fermentation studies. The solid-state fermentation was performed at 37 °C for 30 days using Chuanxiong Rhizoma fermentation medium (40 g Chuanxiong Rhizoma powder, 100 mL sterile water, 121 °C, sterilization for 25 minutes). UPLC was used to detect the contents of ligustrazine, acetoin in the Chuanxiong Rhizoma fermentation medium and Chuanxiong Rhizoma. All the five strains were Gram-positive and had spores. Phylogenetic analysis of the 16S rRNA sequence showed that the endophytes were
B. subtilis. The results of UPLC showed that ligustrazine was detected in the Chuanxiong Rhizoma fermentation medium inoculated with endogenetic
B. subtilis LB3, LB3–2-1, LB4, LB5 and LB6–2, while not detected both in blank Chuanxiong Rhizoma fermentation medium and in Chuanxiong Rhizoma. This study showed that the endogenetic
B. subtilis of
Ligusticum chuanxiong Hort. can make use of Chuanxiong Rhizoma fermentation medium to produce ligustrazine. Endogenetic
B. subtilis has a certain correlation with the accumulation of ligustrazine in Chuanxiong Rhizoma. We speculate that the ligustrazine may be derived from the catabolism of endogenetic
B. subtilis in
Ligusticum chuanxiong.
In order to analyze the law of membrane permeation of different alkaloids, seven traditional Chinese medicine alkaloids with different parent nucleus and substituent structures, including berberine, palmatine, sinomenine, matrine, oxymatrine, sophocarpine, and tetrandrine, were prepared into the simulated solution with same molar concentration, and the membrane penetrating experiments with membrane RC1K and membrane RC5K were carried out. The dynamic permeability, the total permeability and the total adsorption rate of each substance were measured, and the scanning electron microscopy (SEM) images of the membrane surface before and after the membrane experiment were considered to predict and analyze the reason of differences in dynamic permeability of different alkaloids. The results showed that there were significant differences in the dynamic permeability of the chemical components of different alkaloids during penetrating the two membranes. The contamination degree on the surface of the membrane material was also different. The permeability of the same compound through the RC5K membrane was larger than that through RC1K membrane. Within a certain range, the smaller the pore size of the membrane, the better the selective screening effect on the chemical components of traditional Chinese medicine. All the membrane surfaces were less polluted. The difference in permeability between different substances on the same membrane showed a positive correlation with the difference in structural complexity, providing an experimental basis for the surface modification design in contamination control of membrane materials. In the design of membrane modified material, the surface properties of the membrane can be improved by grafting different polar groups, thereby changing the adsorption characteristics of the membrane surface. The pore size was designed accordingly to achieve the high permeability and low pollution of the corresponding compounds.
A new naphthaldehyde derivative has been isolated from
Comastoma pulmonarium by using various chromatographic techniques, including silica gel, Sephadex LH-20, MCI-gel resin and RP-HPLC. This compounds was determined as 5-methoxy-2-methyl-7-(2-oxopropyl) naphthalene-1-carbaldehyde (1) by NMR, MS, IR and UV spectra. This compound was also evaluated for its anti-tobacco mosaic virus (anti-TMV) activity. The result showed that it showed high anti-TMV activity with inhibition rate of 32.8%. The inhibition rate is close to that of positive control (ningnanmycin).
Fructus Arctii is a traditional Chinese medicine. The main counterfeit species are the seeds of
Arctium tomentosum,
Onopordum acanthium,
Silybum marianum,
Saussurea costus, and
Amorpha fruticosa. Traditional identification methods or molecular barcoding techniques can identify Fructus Arctii and its counterfeit species. However, the identification of the mixture of it and its spurious species is rarely reported. In this paper, we sequenced the ITS2 sequences of Fructus Arctii and 5 kinds of spurious species mix powder by high-throughput sequencing to identify the mixed powder species and providing new ideas for the identification of Fructus Arctii mix powder. The total DNA in mixed powder was extracted, and the ITS2 sequences in total DNA were amplified. Paired-end sequencing was performed on the DNA fragment of the community using the Illumina MiSeq platform. The sequence was analyzed by the software FLASH, QIIME and GraPhlAn, etc. The results showed that the high quality ITS2 sequences of 39 910 mix samples were obtained from the mixed samples, of which the total ITS2 sequence of the samples genus was 34 935. Phylogenetic analysis showed that the samples contained Fructus Arctii,
A. tomentosum,
O. acanthium,
S. marianum,
S. costus and
A. fruticosa. Using ITS2 sequences as DNA barcodes, high-throughput sequencing technology can be used to detect the Fructus Arctii and its spurious specie in mixed powder, which can provide reference for the quality control, safe use of medicinal materials of Fructus Arctii and the identification of mixed powder of traditional Chinese medicine.
